Sorrento Therapeutics Inc (SRNE)

[PAUL and Ola]

OK, but it seems to be another reflection of Sorrento deeming their role in the biopharma universe as that of a highly evolved research center – or institute, with production of salable products really pretty secondary or shoved into the distant future, i.e., 2-5 years from now while investors cool their heels because they are trapped, unless I am getting something wrong here. This does not excite or inspire investors. The share price is languishing accordingly. Quality over timeliness? That doesn’t fly. Quality at t=infinity doesn’t get it. Yeah, setting things up for another acquisition or something, maybe. ANP? I guess ACEA is done, but ANP is in limbo or investors are being kept in the dark.